Vitamin D supplementation and mortality risk in chronic kidney disease: A meta-analysis of 20 observational studies

BMC Nephrology

Volumn 14, Issue 1, 2013, Pages

  Zheng, Zhenfeng ^a   Shi, Huilan ^a   Jia, Junya ^a   Li, Dong ^a   Lin, Shan ^a  

^a TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

Calcitriol; Chronic kidney disease; Mortality; Paricalcitol; Vitamin D

Indexed keywords

22 OXACALCITRIOL; ALFACALCIDOL; CALCITRIOL; COLECALCIFEROL; DOXERCALCIFEROL; FALECALCITRIOL; PARATHYROID HORMONE; PARICALCITOL; PHOSPHORUS; RECOMBINANT ERYTHROPOIETIN; VITAMIN D;

ARTICLE; BLOOD PRESSURE; BODY MASS; CARDIOVASCULAR MORTALITY; CHECKLIST; CHRONIC KIDNEY DISEASE; COCHRANE LIBRARY; DIALYSIS; EMBASE; FOLLOW UP; HAZARD RATIO; HEMODIALYSIS PATIENT; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERPHOSPHATEMIA; KIDNEY FAILURE; MEDLINE; META ANALYSIS; OBSERVATIONAL STUDY; VITAMIN SUPPLEMENTATION; CHRONIC KIDNEY FAILURE; COMORBIDITY; DIET SUPPLEMENTATION; INCIDENCE; MORTALITY; RENAL REPLACEMENT THERAPY; REVIEW; RISK FACTOR; SURVIVAL RATE; TREATMENT OUTCOME; VITAMIN D DEFICIENCY;

COMORBIDITY; DIETARY SUPPLEMENTS; HUMANS; INCIDENCE; RENAL DIALYSIS; RENAL INSUFFICIENCY, CHRONIC; RISK FACTORS; SURVIVAL RATE; TREATMENT OUTCOME; VITAMIN D; VITAMIN D DEFICIENCY;

EID: 84884518472     PISSN: None     EISSN: 14712369     Source Type: Journal    
DOI: 10.1186/1471-2369-14-199     Document Type: Article

References (57)

1. Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Moe S, Drueke T, Cunningham J, Goodman W, Martin K, Olgaard K, Ott S, Sprague S, Lameire N, Eknoyan G, et al. Kidney Int 2006 69 1945 1953 10.1038/sj.ki.5000414 16641930 (Pubitemid 43924257)
2. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. Goodman WG, Goldin J, Kuizon BD, Yoon C, Gales B, Sider D, Wang Y, Chung J, Emerick A, Greaser L, et al. N Engl J Med 2000 342 1478 1483 10.1056/NEJM200005183422003 10816185 (Pubitemid 30318271)
3. Cardiovascular calcification in patients with end-stage renal disease: a century-old phenomenon. Qunibi WY, Nolan CA, Ayus JC, Kidney Int 2002 62 Suppl 73 80
4. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM, J Am Soc Nephrol 2004 15 2208 2218 10.1097/01.ASN.0000133041.27682.A2 15284307 (Pubitemid 39031360)
5. 25(OH)D levels and albuminuria in the Third National Health and Nutrition Examination Survey (NHANES III). De Boer I, Ioannou GN, Kestenbaum B, Brunzell JD, Weiss NS, Am J Kidney Dis 2007 50 69 77 10.1053/j.ajkd.2007.04.015 17591526 (Pubitemid 46962855)
6. Plasma 25(OH)D levels and risk of incident hypertension. Forman JP, Giovannucci E, Holmes MD, Bischoff-Ferrari HA, Tworoger SS, Willett WC, Curhan GC, Hypertension 2007 49 1063 1069 10.1161/HYPERTENSIONAHA.107.087288 17372031 (Pubitemid 351664326)
7. Vitamin D and calcium intake in relation to type 2 diabetes in women. Pittas AG, Dawson-Hughes B, Li T, Van Dam RM, Willett WC, Manson JE, Hu FB, Diabetes Care 2006 29 650 656 10.2337/diacare.29.03.06.dc05-1961 16505521 (Pubitemid 44115368)
8. Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: The Dialysis Outcomes and Practice Patterns Study (DOPPS). Tentori F, Blayney MJ, Albert JM, Gillespie BW, Kerr PG, Bommer J, Young EW, Akizawa T, Akiba T, Pisoni RL, et al. Am J Kidney Dis 2008 52 519 530 10.1053/j.ajkd.2008.03.020 18514987
9. Secondary hyperparathyroidism is associated with higher mortality in men with moderate to severe chronic kidney disease. Kovesdy CP, Ahmadzadeh S, Anderson JE, Kalantar-Zadeh K, Kidney Int 2008 73 1296 1302 10.1038/ki.2008.64 18337714 (Pubitemid 351693159)
10. Vitamin D and cardiovascular system. Artaza JN, Mehrotra R, Norris KC, Clin J Am Soc Nephrol 2009 4 1515 1522 10.2215/CJN.02260409 19696220
11. Systematic review: Vitamin D and calcium supplementation in prevention of cardiovascular events. Wang L, Manson JE, Song Y, Sesso HD, Ann Intern Med 2010 152 315 323 10.7326/0003-4819-152-5-201003020-00010 20194238
12. Systematic review: Vitamin D and cardiometabolic outcomes. Pittas AG, Chung M, Trikalinos T, Brendel M, Patel K, Lichtenstein AH, Lau J, Balk EM, Ann Intern Med 2010 152 307 314 10.7326/0003-4819-152-5-201003020-00009 20194237
13. Vitamin D supplementaion in chronic kidney disease: A systematic review and meta-analysis of observational studies and randomized controlled trials. Kandula P, Dobre M, Schold JD, Schreiber MJ, Mehrotra R, Navaneethan SD, Clin J Am Soc Nephrol 2011 6 50 62 10.2215/CJN.03940510 20876671
14. Identifying relevant studies for systematic reviews. Dickersin K, Scherer R, Lefebvre C, BMJ 1994 309 6964 1286 1291 10.1136/bmj.309.6964.1286 7718048 (Pubitemid 24340510)
15. Development of sensitive search strategy for reports of randomized controlled trials in EMBASE. Lefebvre C, McDonald S, Fourth International Cochrane Colloquium: Oct 20-24 1996; Adelaide Adelaide (Australia): The Australian Cochrane Centre 1996
16. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) Group. Meta-analysis of observational studies in epidemiology. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, Moher D, Becker BJ, Sipe TA, Thacker SB, JAMA 2000 283 15 2008 2012 10.1001/jama.283.15.2008 10789670 (Pubitemid 30214957)
17. Wells GA, Shea B, O'Connell D, Peterson J, Welch V, Losos M, Tugwell P, The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analysis Ottawa, Canada: Department of Epidemiology and Community Medicine, University of Ottawa 2010 http://www.ohri.ca/programs/ clinical-epidemiology/oxford.asp
18. STROBE Initiative: Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP, BMJ 2007 335 7624 806 808 10.1136/bmj.39335.541782.AD 17947786 (Pubitemid 350057266)
19. Quantifying heterogeneity in a meta-analysis. Higgins JPT, Thompson SG, Stat Med 2002 21 11 1539 1558 10.1002/sim.1186 12111919 (Pubitemid 34746062)
20. 2 index? Huedo-Medina TB, Sánchez-Meca J, Marín-Martínez F, Botella J, Psychol Methods 2006 11 2 193 206 16784338 (Pubitemid 44001277)
21. Measuring inconsistency in meta-analysis. Higgins JP, Thompson SG, Deeks JJ, Altman DG, BMJ 2003 327 7417 557 560 12958120
22. Operating characteristics of a rank correlation test for publiction bias. Begg CB, Mazumdar M, Biometrics 1994 50 4 1088 1101 10.2307/2533446 7786990
23. Bias in meta-analysis detected by a simple graphical test. Egger M, Davey SG, Schneider M, Minder C, BMJ 1997 315 7109 629 634 10.1136/bmj.315.7109.629 9310563 (Pubitemid 27387172)
24. Contour-enhanced meta-analysis funnel plots help distinguish publication bias from other causes of asymmetry. Peters JL, Sutton AJ, Jones DR, Abrams KR, Rushton L, J Clin Epidemiol 2008 61 10 991 996 10.1016/j.jclinepi.2007.11.010 18538991
25. Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. Teng M, Wolf M, Lowrie E, Ofsthun N, Lazarus JM, Thadhani R, N Engl J Med 2003 349 5 446 456 10.1056/NEJMoa022536 12890843 (Pubitemid 36910023)
26. Lower risk for cardiovascular mortality in oral 1alpha-hydroxy vitamin D3 users in a haemodialysis population. Shoji T, Shinohara K, Kimoto E, Emoto M, Tahara H, Koyama H, Inaba M, Fukumoto S, Ishimura E, Miki T, et al. Nephrol Dial Transplant 2004 19 1 179 184 10.1093/ndt/gfg513 14671054 (Pubitemid 38072630)
27. Activated injectable vitamin D and hemodialysis survival: a historical cohort study. Teng M, Wolf M, Ofsthun MN, Lazarus JM, Hernán MA, Camargo CA Jr, Thadhani R, J Am Soc Nephrol 2005 16 4 1115 1125 10.1681/ASN.2004070573 15728786 (Pubitemid 41710323)
28. Changes in serum calcium, phosphate, and PTH and the risk of death in incident dialysis patients: a longitudinal study. Melamed ML, Eustace JA, Plantinga L, Jaar BG, Fink NE, Coresh J, Klag MJ, Powe NR, Kidney Int 2006 70 2 351 357 10.1038/sj.ki.5001542 16738536 (Pubitemid 44086585)
29. Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. Kalantar-Zadeh K, Kuwae N, Regidor DL, Kovesdy CP, Kilpatrick RD, Shinaberger CS, McAllister CJ, Budoff MJ, Salusky IB, Kopple JD, Kidney Int 2006 70 4 771 780 10.1038/sj.ki.5001514 16820797 (Pubitemid 44215354)
30. Mortality risk among hemodialysis patients receiving different vitamin D analogs. Tentori F, Hunt WC, Stidley CA, Rohrscheib MR, Bedrick EJ, Meyer KB, Johnson HK, Zager PG, Medical Directors of Dialysis Clinic Inc, Kidney Int 2006 70 10 1858 1865 10.1038/sj.ki.5001868 17021609 (Pubitemid 44684819)
31. Association of activated vitamin D treatment and mortality in chronic kidney disease. Kovesdy CP, Ahmadzadeh S, Anderson JE, Kalantar-Zadeh K, Arch Intern Med 2008 168 4 397 403 10.1001/archinternmed.2007.110 18299495 (Pubitemid 351350586)
32. Oral active vitamin D is associated with improved survival in hemodialysis patients. Naves-Díaz M, Alvarez-Hernández D, Passlick-Deetjen J, Guinsburg A, Marelli C, Rodriguez-Puyol D, Cannata-Andía JB, Kidney Int 2008 74 8 1070 1078 10.1038/ki.2008.343 18633342
33. Ratio of paricalcitol dosage to serum parathyroid hormone level and survival in maintenance hemodialysis patients. Shinaberger CS, Kopple JD, Kovesdy CP, McAllister CJ, van Wyck D, Greenland S, Kalantar-Zadeh K, Clin J Am Soc Nephrol 2008 3 6 1769 1776 10.2215/CJN.01760408 18701614
34. Association of oral calcitriol with improved survival in nondialyzed CKD. Shoben AB, Rudser KD, de Boer IH, Young B, Kestenbaum B, J Am Soc Nephrol 2008 19 8 1613 1619 10.1681/ASN.2007111164 18463168
35. Impact of activated vitamin D and race on survival among hemodialysis patients. Wolf M, Betancourt J, Chang Y, Shah A, Teng M, Tamez H, Gutierrez O, Camargo CA Jr, Melamed M, Norris K, et al. J Am Soc Nephrol 2008 19 7 1379 1388 10.1681/ASN.2007091002 18400938
36. The survival advantage for haemodialysis patients taking vitamin D is questioned: findings from the Dialysis Outcomes and Practice Patterns Study. Tentori F, Albert JM, Young EW, Blayney MJ, Robinson BM, Pisoni RL, Akiba T, Greenwood RN, Kimata N, Levin NW, et al. Nephrol Dial Transplant 2009 24 3 963 972 19028748
37. Effects of monthly dose and regular dosing of intravenous active vitamin D use on mortality among patients undergoing hemodialysis. St Peter WL, Li S, Liu J, Gilbertson DT, Arneson TJ, Collins AJ, Pharmacotherapy 2009 29 2 154 164 10.1592/phco.29.2.154 19170585
38. Effectiveness of recombinant human erythropoietin, vitamin D3 and iron therapy on long-term survival of patients with end-stage renal disease receiving haemodialysis: analysis of 702 patients after 10-year follow-up. Chang HC, Chen CL, Chiu TL, Chen SI, Yen AM, Chen TH, Public Health Nutr 2009 12 12 2410 2415 10.1017/S1368980009005308 19344540
39. Patient survival and the combination of vitamin D and phosphorus binder in dialysis. Konta T, Hoshikawa M, Takasaki S, Ichikawa K, Mashima Y, Takahashi T, Abiko H, Masakane I, Matsunaga T, Suzuki M, et al. Dialysis and Transplantation 2010 39 10 427 431 10.1002/dat.20495
40. Administration of alfacalcidol for patients with predialysis chronic kidney disease may reduce cardiovascular disease events. Sugiura S, Inaguma D, Kitagawa A, Murata M, Kamimura Y, Sendo S, Hamaguchi K, Nagaya H, Tatematsu M, Kurata K, et al. Clin Exp Nephrol 2010 14 1 43 50 10.1007/s10157-009-0233-z 19882205
41. ARNOS Study Investigators: Impact of hypovitaminosis D and alfacalcidol therapy on survival of hemodialysis patients: results from the French ARNOS study. Jean G, Lataillade D, Genet L, Legrand E, Kuentz F, Moreau-Gaudry X, Fouque D, Nephron Clin Pract 2011 118 2 204 c210 10.1159/000321507 21178377
42. Secondary hyperparathyroidism in chronic dialysis patients: results of the Italian FARO survey on treatment and mortality. Brancaccio D, Cozzolino M, Cannella G, Messa P, Bonomini M, Cancarini G, Caruso MR, Cascone C, Costanzo AM, di Luzio PU, et al. Blood Purif 2011 32 2 124 132 10.1159/000325454 21625082
43. Vitamin D supplementation and mortality in patients with end-stage renal disease. Dierkes J, Kropf S, Machlitt P, Domroese U, Neumann K, Westphal S, Luley C, Heinz J, Ann Nutr Metab 2011 58 Suppl 3 326
44. Effect of alfacalcidol therapy on the survival of chronic hemodialysis patients. Ogawa M, Ogawa T, Inoue T, Otsuka K, Nitta K, Ther Apher Dial 2012 16 3 248 253 10.1111/j.1744-9987.2012.01061.x 22607568
45. Vitamin D, the renin-angiotensin system, and insulin resistance. Rammos G, Tseke P, Ziakka S, Int Urol Nephrol 2008 40 419 426 10.1007/s11255-007-9244-4 18193490
46. Hypovitaminosis D is associated with insulin resistance and beta cell dysfunction. Chiu KC, Chu A, Go VL, Saad MF, Am J Clin Nutr 2004 79 820 825 15113720 (Pubitemid 41103882)
47. 1,25-Dihydroxyvitamin D3 and rat vascular smooth muscle cell growth. Carthy EP, Yamashita W, Hsu A, Ooi BS, Hypertension 1989 13 954 959 10.1161/01.HYP.13.6.954 2786849 (Pubitemid 19157996)
48. Vitamin D and its analogues: do they protect against cardiovascular disease in patients with kidney disease? Levin A, Li YC, Kidney Int 2005 68 1973 1981 10.1111/j.1523-1755.2005.00651.x 16221197 (Pubitemid 43117772)
49. 1,25-Dihydroxyvitamin D3 modulates expression of chemokines and cytokines in pancreatic islets: implications for prevention of diabetes in nonobese diabetic mice. Gysemans CA, Cardozo AK, Callewaert H, Giulietti A, Hulshagen L, Bouillon R, Eizirik DL, Mathieu C, Endocrinology 2005 146 1956 1964 10.1210/en.2004-1322 15637289 (Pubitemid 40396905)
50. 1,25-dihydroxyvitamin D(3) and its potent synthetic analogs downregulate tissue factor and upregulate thrombomodulin expression in monocytic cells, counteracting the effects of tumor necrosis factor and oxidized LDL. Ohsawa M, Koyama T, Yamamoto K, Hirosawa S, Kamei S, Kamiyama R, Circulation 2000 102 2867 2872 10.1161/01.CIR.102.23.2867 11104746
51. Characterization of heart size and blood pressure in the vitamin D receptor knockout mouse. Simpson RU, Hershey SH, Nibbelink KA, J Steroid Biochem Mol Biol 2007 103 521 524 10.1016/j.jsbmb.2006.12.098 17275289 (Pubitemid 46420533)
52. Predictors and consequences of altered mineral metabolism: the Dialysis Outcomes and Practice Patterns Study. Young EW, Albert JM, Satayathum S, Goodkin DA, Pisoni RL, Akiba T, Akizawa T, Kurokawa K, Bommer J, Piera L, et al. Kidney Int 2005 67 1179 1187 10.1111/j.1523-1755.2005.00185.x 15698460 (Pubitemid 41623345)
53. Marginal structural models and causal inference in epidemiology. Robins JM, Hernan MA, Brumback B, Epidemiology 2000 11 550 560 10.1097/00001648- 200009000-00011 10955408 (Pubitemid 30660034)
54. Correction for non-compliance in equivalence trials. Robins JM, Stat Med 1998 17 269 302 10.1002/(SICI)1097-0258(19980215)17:3<269::AID-SIM763>3.0. CO;2-J 9493255 (Pubitemid 28051099)
55. Effect of highly active antiretroviral therapy on time to acquired immunodeficiency syndrome or death using marginal structural models. Cole SR, Hernan MA, Robins JM, Anastos K, Chmiel J, Detels R, Ervin C, Feldman J, Greenblatt R, Kingsley L, et al. Am J Epidemiol 2003 158 687 694 10.1093/aje/kwg206 14507605 (Pubitemid 37175517)
56. Differential effects of vitamin D analogs on vascular calcifiction. Cardus A, Panizo S, Parisi E, Fernandez E, Valdivielso JM, J Bone Miner Res 2007 22 860 866 10.1359/jbmr.070305 17352647 (Pubitemid 351339746)
57. Differential effects if vitamin D receptor activators on vascular calcification in uremic rats. Mizobuchi M, Finch JL, Martin DR, Slatopolsky E, Kidney Int 2007 72 709 715 10.1038/sj.ki.5002406 17597697 (Pubitemid 47373790)